Skip to contentpdufa.bio

KRRO-121 (GalNAc RNA-editing oligonucleotide)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

KRRO-121 (GalNAc RNA-editing oligonucleotide) is a Korro Bio, Inc. program in urea cycle disorders (hyperammonemia). Its next catalyst is a Readout in Q4 2027.

KRRO catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Urea cycle disorders (hyperammonemia). Sponsor: Korro Bio, Inc. (KRRO). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027KRRO

Questions

When is KRRO-121 (GalNAc RNA-editing oligonucleotide)'s next FDA decision or readout?

The next tracked catalyst for KRRO-121 (GalNAc RNA-editing oligonucleotide) is a Readout in Q4 2027.

What happened at KRRO-121 (GalNAc RNA-editing oligonucleotide)'s most recent FDA decision?

No FDA decision for KRRO-121 (GalNAc RNA-editing oligonucleotide) is in our archive yet.

What is KRRO-121 (GalNAc RNA-editing oligonucleotide) used for?

In our records KRRO-121 (GalNAc RNA-editing oligonucleotide) is under review or in development for Urea cycle disorders (hyperammonemia).

Who makes KRRO-121 (GalNAc RNA-editing oligonucleotide)?

Korro Bio, Inc. (KRRO).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.